has been shown to be a better predictor of cardiovascular/metabolic disease in nonobese subjects, which may account for this finding. HIV infection was not associated with GDM. The use of cART, particularly, protease inhibitors, has been associated with insulin resistance in pregnant and nonpregnant women. The low rates of cART (33 of 166) and protease inhibitor (1 of 166) use in the HIV-infected subgroup may explain why an association between HIV and GDM was not found in our study. Among HIV-infected women, GDM was associated with higher blood pressure. Almost all (91%) of the HIV-infected women with GDM were on cART. Our cohort had insufficient numbers of HIV-infected women not on cART with GDM to create an adequately powered multivariate model. Nonetheless, the significant association between cART and GDM in univariate analysis is consistent with reports in developed countries.
Our study is limited by its small sample size. The low rates of cART use limited our ability to assess effects of HIV/cART on GDM. Lastly, we could not properly evaluate effects of GDM on birth weight, since subjects delivered at different facilities.
Our study revealed a GDM rate within the range of that in advanced economies, evidence for the growing prevalence of diabetes in Africa, which is projected to 
